Abstract 17P
Background
Ovarian cancer is the most lethal gynecological malignancy worldwide and is known to have a poor prognosis among gynecological cancers. Recently, PD-1/PD-L1 inhibitors have demonstrated promising clinical outcomes in the treatment of OC. However, only about 20% of patients respond to these therapies, highlighting the need for improved patient selection. LncRNAs are significantly involved in tumor proliferation, apoptosis, migration, and metastasis and have significant associations with immune cell infiltration and the cancer cell response to anti-PD-1 immunotherapy in various tumors. Based on reports that immune-related lncRNAs play a role in regulating the PD-1/PD-L1 mechanism, this study aims to identify predictive biomarkers for ovarian cancer.
Methods
We analyzed the mRNA and protein levels of PD-L1 in OC patient tissues and classified them into high and low PD-L1 expression groups. We performed lncRNA microarray analysis on the classified groups. As a result, we identified MIR4435-2HG as lncRNA associated with PD-L1 overexpression. Furthermore, MIR4435-2HG knockdown were conducted. Other features, including cell growth, apoptosis, migration and invasion were also analyzed.
Results
A positive correlation between PD-L1 and MIR4435-2HG was observed in both OC tissues and cell lines. Knockdown of MIR4435-2HG in OC cell lines resulted in decreased PD-L1 expression and induce cellular apoptosis and inhibit cell migration and invasion. Moreover, GO analysis revealed that MIR4435-2HG is associated to immune-related genes.
Conclusions
Therefore, this study suggests that the lncRNA MIR4435-2HG associated with PD-L1 may be used as a predictive biomarker and therapeutic target in ovarian cancer.
Legal entity responsible for the study
The Catholic University of Korea, Industry-Academic Cooperation Foundation.
Funding
The National Research Foundation of Korea (NRF).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract
204P - Deciphering the crosstalk between tumor and circulating immune microenvironment in advanced NSCLC patients undergoing immunotherapy
Presenter: Prisca Tamarozzi
Session: Poster Display session
Resources:
Abstract